Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-135993 · Präparat HOS-097800
Acute pancreatitis The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical trials was 0.3% for semaglutide and 0.2% for the comparator, respectively. In the 2-year cardiovascular outcomes trial the frequency of acute pancreatitis confirmed by adjudication was 0.5% for semaglutide and 0.6% for placebo (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 586a30135fac8f985b71805b5d7893d1ad171b3d6f94f41e8a1c7f78e2b403b1 · Zeichen 8573–8926 im Abschnitt